Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Canada: Hema-Fer Is Safe to Prevent Iron Deficiency During Pregnancy

By VANC Pharmaceuticals Inc. | August 25, 2017

Vanc Pharmaceuticals receives updated Health Canada approval for Hema-Fer with new indication for use in pregnancy.

Vanc Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, announces that it has received Health Canada Class-III approval for Hema-Fer.

Vanc is pleased to announce that Hema-Fer has received Class-III approval from Health Canada under NPN 80079606 along with expanded dosing guidelines to include a recommendation for use in pregnancy. This re-categorization was requested by Health Canada, and Vanc used this opportunity to update our dosing recommendations to clearly communicate to consumers that Hema-Fer is safe to use in pregnancy to prevent iron deficiency and iron deficiency anemia.

“We are extremely pleased to receive approval in such a short period of time and excited to be able to include this new recommendation for pregnant women,” says Mr. Bob Rai, CEO. “Hema-Fer is already free of many key allergens and one of the best tolerated and best absorbed iron supplements and having a recommendation for safe use in pregnancy has Hema-Fer well positioned to increase its market share. 

“Our team responded to Health Canada’s new guidelines in an impressive fashion bringing Hema-Fer back to the market with little disruption as well as a broader label. This is a significant milestone we’ve been able to achieve in such short order and we look forward to updating our shareholders with many more near term catalysts over the coming months,” concluded Mr. Rai.

Hema-Fer, currently the most potent heme iron supplement available in Canada, was launched in January 2016 and has gained strong traction in the growing Canadian iron supplement market, which was valued at $46 million dollars in 2016 alone.

Working with our manufacturers, Vanc has ensured Hema-Fer is gluten-free, and does not contain peanuts, hydrogenated vegetable oil (HVO), pork, and many other key allergens. These distinguishing factors allow health care professionals to broadly recommend Hema-Fer to patients with a wide range of allergies and diet preferences, representing a key market advantage.

(Source: GlobeNewswire)

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards